Pharsight

Pliaglis generic

Pliaglis is a topical anesthetic cream owned by Taro Pharms, containing active ingredients Lidocaine and Tetracaine. The drug was first authorized for market use on 29 June, 2006.

When will Pliaglis generic be available?

With the last patent for Pliaglis expiring on 14 January, 2031, the generics of Pliaglis may be available on the market after that date. This is based on current patent protection rights, and no early generic release due to Para IV filing is noted for Pliaglis.

Pliaglis uses

Pliaglis is used for pain control. Its effectiveness is derived from its unique formulation that solidifies on the skin, allowing the active ingredients, Lidocaine and Tetracaine, to numb the applied area effectively.

Pliaglis patent expiration

Pliaglis holds three patents, all focusing on its solid-forming, local anesthetic formulation for effective pain control. These patents are set to expire on 14 January, 2031. After this date, Pliaglis generics may become available. Below are the details of the patent:

Pliaglis dosage

Want to ask something?